title: Lessons in AIDS vaccine development learned from studies of equine infectious, anemia virus infection and immunity.
abstract: Equine infectious anemia (EIA), identified in 1843 [1] as an infectious disease of horses and as a viral infection in 1904, remains a concern in veterinary medicine today. Equine infectious anemia virus (EIAV) has served as an animal model of HIV-1/AIDS research since the original identification of HIV. Similar to other lentiviruses, EIAV has a high propensity for genomic sequence and antigenic variation, principally in its envelope (Env) proteins. However, EIAV possesses a unique and dynamic disease presentation that has facilitated comprehensive analyses of the interactions between the evolving virus population, progressive host immune responses, and the definition of viral and host correlates of immune control and vaccine efficacy. Summarized here are key findings in EIAV that have provided important lessons toward understanding long term immune control of lentivirus infections and the parameters for development of an enduring broadly protective AIDS vaccine.
authors: Center for Vaccine Research, Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA 15261, USA. rmont@pitt.edu.
authors: Jodi K
authors: JK
authors: Craigo
authors: Ronald C
authors: RC
authors: Montelaro
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology* / Q000302:isolation & purification*; D000818:Animals; D000940:Antigenic Variation; D055808:Drug Discovery / Q000639:trends*; D004859:Equine Infectious Anemia / Q000276:immunology* / Q000517:prevention & control*; D014644:Genetic Variation; D006736:Horses; D006801:Humans; D004860:Infectious Anemia Virus, Equine / Q000235:genetics / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines